Abstract:KEYWORDS: The mitochondrial permeability transition (MPT) is defined as the loss of inner membrane a specific impermeability and transmembrane potential, due to the sustained opening of a large pore (the MPTP). The pore (also nicknamed Mitochondrial MegaChannel, MMC) has been characterized decades ago in studies with isolated mitochondria and – by our group – by single-channel patch-clamp on rat liver mitoplasts. Very similar activity (the Multi-Conductance Channel, MCC) was independently described by K.W. Kinnally's group (revs [ Citation 1 , Citation 2 ]). The awakening of this megachannel is elicited by increases in matrix Ca 2+ levels and is potentiated by other agents/processes, the major one being oxidative stress. The equivalent diameter of the pore can be as large as 3 nm but the channel exhibits a variety of sizes. In samples of isolated mitochondria, the molecular weight of permeating molecules increases as a function of the inducing Ca 2+ concentration and of the time elapsed since induction. Partial removal of the OMM would instead tend to decrease it [ Citation 3 ]. Prolonged opening is accompanied by depolarization, release of matrix components, further generation of reactive oxygen species (ROS), morphological changes (swelling, fragmentation of the mitochondrial network), decrease in cellular ATP levels, activation of mitophagy and, eventually, cell death. MPTP opening has been proposed to be involved in ischemia/reperfusion injury (IRI), aging and aging-associated neurodegenerative diseases, chronic stress syndrome, traumatic brain injury, muscular dystrophy, diabetes, cirrhosis, pancreatitis, osteoporosis, and more. In addition, cancer cells deploy desensitization mechanisms which help cancer growth and dispersion, and which may oppose chemotherapy. Inhibiting or activating the MPTP is therefore an exceptionally relevant pharmacological goal. As such, it has received much attention, but so far successes in pre-clinical models have not been accompanied by a proportionate impact in clinical practice. The effort continues. The MPTP is also believed to have physiological and protective roles under normal circumstances, by opening transiently to act as a 'Ca 2+ release valve,' preventing mitochondrial Ca 2+ overload, and tuning mitochondrial function [ Citation 4 , Citation 5 ]. This function appears to be particularly important in cardiac myocytes.

The adenine nucleotide translocase family underlies cardiac ischemia-reperfusion injury through the mitochondrial permeability pore independently of cyclophilin D

The mitochondrial ATP synthase is a negative regulator of the mitochondrial permeability transition pore

Inhibition of the mPTP and Lipid Peroxidation Is Additively Protective Against I/R Injury

Refractive Index Imaging Reveals That Elimination of the ATP Synthase C Subunit Does Not Prevent the Adenine Nucleotide Translocase-Dependent Mitochondrial Permeability Transition

Protective Role of Transient Pore Openings in Calcium Handling by Cardiac Mitochondria

Cyclophilin D-mediated Mitochondrial Permeability Transition Regulates Mitochondrial Function

Rationale : Mice lacking cyclophilin

Modulation of mitochondrial permeability transition pores in reperfusion injury: Mechanisms and therapeutic approaches

Endogenous complement 1q binding protein (C1qbp) regulates mitochondrial permeability transition and post-myocardial infarction remodeling and dysfunction

Mechanistic correlation between mitochondrial permeability transition pores and mitochondrial ATP dependent potassium channels in ischemia reperfusion

Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions

The Role of Mitochondrial Permeability Transition Pore in Ischemia/reperfusion Injury

Calpain-mediated protein targets in cardiac mitochondria following ischemia–reperfusion

Inhibition of mitochondrial permeability transition by deletion of the ANT family and CypD

Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease

Induction of the permeability transition pore in cells depleted of mitochondrial DNA

Cyclophilin D as a drug target

Mitochondrial fission process 1 (MTFP1) controls bioenergetic efficiency and prevents inflammatory cardiomyopathy and heart failure in mice

Ischemic Preconditioning Inhibits Mitochondrial Permeability Transition Pore Opening Through the PTEN/PDE4 Signaling Pathway.

Mitochondrial permeability transition pore: a snapshot of a therapeutic target

Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death